Monte Rosa Therapeutics (GLUE) announced an agreement to collaborate with Novartis (NVS) to develop novel degraders for immune-mediated diseases. The agreement is the Company’s second with Novartis, in addition to the global exclusive license agreement for Monte Rosa’s VAV1 degraders including MRT-6160, announced in October 2024. The agreement announced was structured by the companies to collaborate on accelerating development of degraders for important immune-mediated diseases driven by highly credentialed and difficult-to-drug targets. Under the agreement, Monte Rosa’s scientists will apply their proprietary AI/ML-enabled QuEEN product engine for the discovery and development of degraders to be further developed and commercialized by Novartis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics Reports Q2 2025 Earnings
- Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential
- Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M
- Monte Rosa Therapeutics management to meet with Piper Sandler
- Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102